+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Adenosine A1 Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A1 Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Androgen Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Androgen Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
From
Heat shock protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Heat shock protein inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Androgen Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Androgen Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Bcl-xL Protein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Bcl-xL Protein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Growth Hormone Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Growth Hormone Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Muscarinic M1 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Muscarinic M1 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
Ghrelin receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Ghrelin receptor agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more